Guy Braunstein, who has served as Idorsia’s (SIX: IDIA) chief medical officer (CMO) since 2022, will retire at the end of this month.
Dr Braunstein has also been head of global clinical development and a member of the Idorsia executive committee since the creation of the Swiss biopharma company.
"We already have the ideal candidate to succeed Guy from within our ranks"He will continue to support Idorsia as an advisor, especially in the analysis and interpretation of the data coming from the programs that he has initiated and led during his time with the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze